TW202035438A - 阿茲海默症之判定藥及判定方法 - Google Patents

阿茲海默症之判定藥及判定方法 Download PDF

Info

Publication number
TW202035438A
TW202035438A TW108127965A TW108127965A TW202035438A TW 202035438 A TW202035438 A TW 202035438A TW 108127965 A TW108127965 A TW 108127965A TW 108127965 A TW108127965 A TW 108127965A TW 202035438 A TW202035438 A TW 202035438A
Authority
TW
Taiwan
Prior art keywords
disease
alzheimer
s38aa
antibody
polypeptide
Prior art date
Application number
TW108127965A
Other languages
English (en)
Chinese (zh)
Inventor
大野篤志
寺西康博
楠本雅典
橋本雅一
柏原昌次
橋本麻生
Original Assignee
日商大日本住友製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大日本住友製藥股份有限公司 filed Critical 日商大日本住友製藥股份有限公司
Publication of TW202035438A publication Critical patent/TW202035438A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
TW108127965A 2018-08-07 2019-08-06 阿茲海默症之判定藥及判定方法 TW202035438A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018148924 2018-08-07
JP2018-148924 2018-08-07

Publications (1)

Publication Number Publication Date
TW202035438A true TW202035438A (zh) 2020-10-01

Family

ID=69413505

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108127965A TW202035438A (zh) 2018-08-07 2019-08-06 阿茲海默症之判定藥及判定方法

Country Status (10)

Country Link
US (1) US12000844B2 (https=)
EP (1) EP3835424A4 (https=)
JP (2) JP7470041B2 (https=)
KR (1) KR20210041035A (https=)
CN (1) CN112567039B (https=)
AU (1) AU2019318888A1 (https=)
CA (1) CA3108440A1 (https=)
MX (1) MX2021001507A (https=)
TW (1) TW202035438A (https=)
WO (1) WO2020032027A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
AU2021218735A1 (en) * 2020-02-13 2022-09-01 Cognition Therapeutics, Inc. Method of decreasing amyloid beta monomer levels in patients with cognitive decline
WO2023036105A1 (zh) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法
CN117447590B (zh) * 2023-11-23 2024-04-26 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体、分泌抗赤羽病病毒单克隆抗体的杂交瘤细胞及其应用
CN121272033A (zh) * 2025-08-21 2026-01-06 广东益尔生物技术有限公司 一种Circ-sAPPα及sAPPα-199aa作为阿尔茨海默症的检测标志物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
SG191620A1 (en) 2008-07-08 2013-07-31 Sumitomo Bakelite Co Positive photosensitive resin composition, cured film, protecting film, insulating film, and semiconductor device and display device using the same
WO2010048497A1 (en) * 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
EP2660600B1 (en) 2010-12-28 2018-08-08 Sumitomo Dainippon Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease
CN109924024B (zh) 2013-03-05 2021-11-23 现特技术有限公司 光子调制管理系统
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法

Also Published As

Publication number Publication date
JP7654126B2 (ja) 2025-03-31
EP3835424A1 (en) 2021-06-16
EP3835424A4 (en) 2022-05-04
US20210165002A1 (en) 2021-06-03
CN112567039A (zh) 2021-03-26
CN112567039B (zh) 2024-11-26
CA3108440A1 (en) 2020-02-13
MX2021001507A (es) 2021-04-28
JP2024054181A (ja) 2024-04-16
JP7470041B2 (ja) 2024-04-17
KR20210041035A (ko) 2021-04-14
AU2019318888A1 (en) 2021-03-18
WO2020032027A1 (ja) 2020-02-13
US12000844B2 (en) 2024-06-04
JPWO2020032027A1 (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
JP7654126B2 (ja) アルツハイマー病の判定薬および判定方法
JP4659025B2 (ja) 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
TWI853145B (zh) Tau蛋白病變及失智症相關疾病之判定藥及判定方法
KR101883515B1 (ko) 알츠하이머 병의 진단약 및 진단 방법
JP2025530718A (ja) 抗タウｍｔｂｒ抗体、ならびにタウの切断された断片の検出方法およびその用途
WO2011005628A1 (en) Detection of neurodegenerative disease
EP2817632B1 (en) New dual biomarker of neurodegeneration and of neuroregeneration
WO2020252394A2 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
CA2878418A1 (en) Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
KR101873971B1 (ko) 뉴레귤린-1 단백질을 이용한 알츠하이머 병 진단용 조성물 및 이를 이용한 알츠하이머 병의 진단방법
JP7343862B2 (ja) 血管障害の判定方法
HK40048565A (en) Diagnostic drug and diagnostic method for alzheimer's disease
HK40077327A (en) Determination agent and determination method for tauopathy and dementia-related diseases
WO2007055341A1 (ja) 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
Guo et al. Autoantibody to the Rab6A/Rab6B in Autoimmune Cerebellar Ataxia Associated with Sjogren’s Syndrome